INBX · Inhibrx Biosciences, Inc.
$103.63
+4.48 (+4.52%)
At close · Aug 21
Market Cap
$1.52B
Shares
14.72M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.3M
+550%
FY2025
Net Income
-$140.06M
-108.3%
FY2025
Operating Margin
-10386.54%
+155337.5pp
FY2025
Diluted EPS
-$9.04
-108%
FY2025
Operating Cash Flow
-$129.79M
+33.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $1.3M | $200K | $1.8M | |
| $103M | $113.03M | $203.74M | $191.64M | |
| $24.81M | $23.3M | $127.91M | $29.38M | |
| $2.21M | $2.48M | $2.29M | $1.19M | |
| $127.81M | $136.33M | $331.65M | $221.02M | |
| -$127.81M | -$135.03M | -$331.45M | -$219.22M | |
| — | -10386.54% | -165724% | -12178.94% | |
| -$125.61M | -$132.54M | -$329.16M | -$218.03M | |
| $15.57M | $12.2M | $13.49M | $31.84M | |
| -$10.37M | -$5.03M | $2.02B | -$20.5M | |
| — | — | $0 | -$1.63M | |
| -$138.18M | -$140.05M | $1.69B | -$239.72M | |
| $3000 | $2000 | $2000 | $3000 | |
| -$138.18M | -$140.06M | $1.69B | -$241.36M | |
| — | -10773.46% | 843786% | -13408.94% | |
| USD/shares | — | -$9.04 | $114.01 | -$20.48 |
| USD/shares | — | -$9.04 | $112.62 | -$20.48 |
| shares | — | 15.49M | 14.8M | 11.78M |
| shares | — | 15.49M | 14.98M | 11.78M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.90×
EV/EBIT
—
Peer median 12.59×
P/E (TTM)
—
Peer median 17.77×
Peer medians compare against the 277 similar-size Biotechnology companies (of 533 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $1,300,000 | $200,000 | $1,800,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| License Non Affiliate | $1,300,000 | $200,000 | $1,800,000 |